Has not received any previous treatment with any approved or investigational drug or drug regimen for the treatment of hepatitis C

Male and female subjects, 18 to 70 years of age, inclusive

Genotype 1, chronic hepatitis C with detectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)

Screening laboratory values, tests, and physical exam within acceptable ranges

Able and willing to follow contraception requirements

Able to read and understand, and willing to sign the informed consent form and abide by the study restrictions

A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)